IDEXX Laboratories Inc logo

IDEXX Laboratories Inc

NEW
NAS:IDXX (USA)   Ordinary Shares
$ 511.65 +5.17 (+1.02%) 10:08 PM EST
35.96
P/B:
25.02
Market Cap:
$ 40.31B
Enterprise V:
$ 41.21B
Volume:
1.11M
Avg Vol (2M):
571.66K
Trade In:
Volume:
1.11M
Avg Vol (2M):
571.66K

Business Description

IDEXX Laboratories Inc logo
IDEXX Laboratories Inc
NAICS : 325412 SIC : 2835
ISIN : US45168D1046

Share Class Description:

IDXX: Ordinary Shares

Total Employee Number:

11,000
Description
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Name Current Vs Industry Vs History
Cash-To-Debt
0.18
Equity-to-Asset
0.47
Debt-to-Equity
0.68
Debt-to-EBITDA
0.68
Interest Coverage
38.6
Piotroski F-Score
9/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score
18.69
Distress
Grey
Safe
Beneish M-Score
-2.7
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI
42.57
9-Day RSI
37.33
14-Day RSI
38.12
3-1 Month Momentum %
-1.56
6-1 Month Momentum %
-4.12
12-1 Month Momentum %
-15.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
1.17
Quick Ratio
0.87
Cash Ratio
0.15
Days Inventory
82.65
Days Sales Outstanding
46.66
Days Payable
25.97

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
1.3
Shareholder Yield %
2.95

Financials (Next Earnings Date:2026-11-03 Est.)

IDXX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:IDXX

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

IDEXX Laboratories Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 4,553.223
EPS (TTM) ($) 14.228
Beta 1.4389
3-Year Sharpe Ratio 0.12
3-Year Sortino Ratio 0.19
Volatility % 29.1
14-Day RSI 38.12
14-Day ATR ($) 14.400331
20-Day SMA ($) 531.205
12-1 Month Momentum % -15.59
52-Week Range ($) 500.61 - 769.98
Shares Outstanding (Mil) 78.78

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

IDEXX Laboratories Inc Filings

Filing Date Document Date Form
No Filing Data

IDEXX Laboratories Inc Stock Events

Financials Calendars
Event Date Price ($)
Annual report for 2026 2027-02-19 In 153 days
Fourth quarter earnings conference call for 2026 2027-02-02 08:30 In 137 days
Fourth quarter earnings results for 2026 2027-02-02 In 136 days
Third quarter earnings conference call for 2026 2026-11-03 08:30 In 46 days
Third quarter earnings results for 2026 2026-11-03 In 45 days
Morgan Stanley 24th Annual Global Healthcare Conference 2026-09-14 10:45 504.70 (-1.02%)
Analyst meeting for 2026 2026-08-13 08:00 570.58 (-1.62%)
Second quarter earnings conference call for 2026 2026-08-04 08:30 567.84 (-0.32%)
Second quarter earnings results for 2026 2026-08-04 567.84 (-0.32%)
Stifel Jaws & Paws Conference 2026-05-27 10:55 557.21 (+0.45%)
Show
Entries

IDEXX Laboratories Inc Frequently Asked Questions

What is IDEXX Laboratories Inc(IDXX)'s stock price today?
The current price of IDXX is $511.65. The 52 week high of IDXX is $769.98 and 52 week low is $500.61.
When is next earnings date of IDEXX Laboratories Inc(IDXX)?
The next earnings date of IDEXX Laboratories Inc(IDXX) is 2026-11-03 Est..
Does IDEXX Laboratories Inc(IDXX) pay dividends? If so, how much?
IDEXX Laboratories Inc(IDXX) does not pay dividend.

Guru Commentaries on NAS:IDXX

2026 Q2
baillie-gifford-us-equity-growth-2026-q2
Baillie Gifford · 274 holdings
What the manager wrote

IDEXX is a global leader in pet healthcare diagnostics, combining testing devices, software applications, and data analytics into a platform that is deeply embedded in veterinary workflows. The company has strong margins, attractive returns, and a significant market position. We see a path to steady growth as testing becomes broader and more frequent. After a five-year period in which the share price has languished, we believe the market has overlooked the business's durability and the quality of the growth opportunity.

2026 Q2
Baron Partners Fund · 30 holdings
What the manager wrote

IDEXX Laboratories, Inc. is mentioned as a holding in the portfolio, but there is no explicit argument made regarding its future performance or valuation. The letter notes that IDEXX Laboratories, Inc. is perceived by investors to be heavily reinvesting in their business at the expense of near-term earnings, which has contributed to lower valuation multiples. However, no specific bullish or bearish stance is taken on the company.

2026 Q2
What the manager wrote

IDEXX Laboratories Inc. was noted as a detractor for the quarter despite posting strong quarterly results. This suggests that while the company may have solid fundamentals, it faced challenges that impacted its performance negatively in the market. The mention of IDEXX as a detractor indicates that the manager is cautious about its current valuation and market position, even if the underlying business remains strong.

2026 Q2
What the manager wrote

IDEXX Laboratories Inc. made the quarterly detractors list despite posting strong quarterly results. This indicates that while the company has solid fundamentals, it faced challenges that impacted its performance negatively during the quarter. The mention of IDEXX as a detractor suggests that the market may not be fully valuing its potential, which could reflect broader concerns in the veterinary diagnostics sector.

2026 Q2
What the manager wrote

IDEXX Laboratories, Inc. is a significant holding in our portfolio, reflecting our long-term investment strategy. The company has been a part of our investments since 2005, and we believe it possesses a sustainable competitive advantage and a vast addressable market. Despite recent valuation declines, we remain optimistic about its growth prospects.

2026 Q1
What the manager wrote

IDEXX Laboratories, Inc. is the leading provider of diagnostics to the veterinary industry and is benefiting from the increase in pets that people acquired during the COVID pandemic, especially as these pets age. The company continues to add new customers and increase the level of spending per customer as they add new articles of clothing and open new stores both domestically and abroad. This has allowed them to grow its addressable market and improve client retention and cash flow.

2026 Q1
BARON ASSET FUND · 50 holdings
What the manager wrote

IDEXX Laboratories, Inc. is mentioned as a holding in the portfolio, but there is no specific argument or directional language provided regarding its future performance or valuation.

2026 Q1
What the manager wrote

IDEXX Laboratories, Inc. is mentioned as part of the portfolio, but there is no specific argument or directional language provided regarding its future performance or valuation.

2025 Q3
Baron Partners Fund · 30 holdings
What the manager wrote

IDEXX Laboratories, Inc. contributed to performance after reporting better-than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Even so, IDEXX’s excellent execution has enabled the company to maintain strong performance. We believe IDEXX’s competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth this year. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should support IDEXX’s long-term growth rate.

2025 Q3
What the manager wrote

IDEXX Laboratories Inc. develops, manufactures, and distributes products and services for animal veterinary, livestock, poultry, and water testing markets. A solid second quarter resulted in a 19% share price appreciation, with innovative tests and consoles driving the upside. The company's focus on novel therapies and premium pricing positions it well in the health care sector, contributing to its growth and market strength.

Headlines

See More
  • 1
Sep 16, 2026
IDEXX Laboratories buys CoVetAI
Seeking Alpha • 6:30am
  • 1